Skip Navigation


Hum. Reprod. Advance Access originally published online on February 22, 2007
Human Reproduction 2007 22(5):1298-1303; doi:10.1093/humrep/dem014
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF ) Freely available
Right arrow All Versions of this Article:
22/5/1298    most recent
dem014v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Franssen, M.T.M.
Right arrow Articles by Goddijn, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Franssen, M.T.M.
Right arrow Articles by Goddijn, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2007. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Management of recurrent miscarriage: evaluating the impact of a guideline

M.T.M. Franssen1,5, J.C. Korevaar2, F. van der Veen1, K. Boer3, N.J. Leschot4 and M. Goddijn1

1 Centre for Reproductive Medicine 2 Department of Clinical Epidemiology and Biostatistics 3 Department of Obstetrics and Gynaecology 4 Department of Clinical Genetics, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands

5 To whom correspondence should be addressed at: Centre for Reproductive Medicine, Academic Medical Centre, University of Amsterdam, H4-205, PO Box 22660, 1100 DD Amsterdam, The Netherlands. E-mail: m.t.franssen{at}amc.uva.nl

BACKGROUND: Little is known on the actual diagnostic and therapeutic management of recurrent miscarriage and the impact of introducing guidelines on this topic. The objective of this study was to evaluate any changes in the management of recurrent miscarriage among Dutch gynaecologists after the introduction of the Dutch guideline ‘Recurrent Miscarriage’ in 1999.

METHODS: Questionnaires were sent to all practices for obstetrics and gynaecology in the Netherlands. Data concerned definition, diagnosis and treatment of recurrent miscarriage. Results were compared with a similar study conducted before the introduction of the guideline and with the recommendations in the guideline.

RESULTS: The response rate was 83%. Regarding gestational age, only 3% of the respondents used the definition as advised in the guideline. After the introduction of the guideline, thrombophilia factors were tested more frequently, anticoagulants were prescribed more frequently and more respondents reported to correct uterine malformations. Therapies not described in the guideline, e.g. donor insemination and oocyte donation, were still applied.

CONCLUSIONS: The adherence to the Dutch guideline ‘Recurrent Miscarriage’ was rather poor, presumably due to guideline-related as well as physician-related barriers. Too many diagnostic tests and ineffective therapeutic interventions were performed. This study demonstrates the importance of appropriate implementation and revision.

Key words: recurrent miscarriage/abortion/implementation/guideline

Submitted on September 20, 2006; resubmitted on December 12, 2006; accepted on January 3, 2007.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.